HUE048715T2 - (1R,5S)-(+)-l-(naftalen-2-il)-3-azabiciklo[3.1.0]hexán alkalmazása monoamin neurotranszmitterek által befolyásolt állapotok kezelésében - Google Patents

(1R,5S)-(+)-l-(naftalen-2-il)-3-azabiciklo[3.1.0]hexán alkalmazása monoamin neurotranszmitterek által befolyásolt állapotok kezelésében

Info

Publication number
HUE048715T2
HUE048715T2 HUE12820058A HUE12820058A HUE048715T2 HU E048715 T2 HUE048715 T2 HU E048715T2 HU E12820058 A HUE12820058 A HU E12820058A HU E12820058 A HUE12820058 A HU E12820058A HU E048715 T2 HUE048715 T2 HU E048715T2
Authority
HU
Hungary
Prior art keywords
naphthalen
azabicyclo
hexane
treatment
monoamine neurotransmitters
Prior art date
Application number
HUE12820058A
Other languages
English (en)
Inventor
Anthony Alexander Mckinney
Frank Bymaster
Original Assignee
Otsuka America Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka America Pharmaceutical Inc filed Critical Otsuka America Pharmaceutical Inc
Publication of HUE048715T2 publication Critical patent/HUE048715T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE12820058A 2011-07-30 2012-07-27 (1R,5S)-(+)-l-(naftalen-2-il)-3-azabiciklo[3.1.0]hexán alkalmazása monoamin neurotranszmitterek által befolyásolt állapotok kezelésében HUE048715T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161574231P 2011-07-30 2011-07-30
US201113334066A 2011-12-22 2011-12-22
US201213528940A 2012-06-21 2012-06-21

Publications (1)

Publication Number Publication Date
HUE048715T2 true HUE048715T2 (hu) 2020-09-28

Family

ID=47629575

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12820058A HUE048715T2 (hu) 2011-07-30 2012-07-27 (1R,5S)-(+)-l-(naftalen-2-il)-3-azabiciklo[3.1.0]hexán alkalmazása monoamin neurotranszmitterek által befolyásolt állapotok kezelésében

Country Status (12)

Country Link
EP (1) EP2819516B1 (hu)
CA (1) CA2843847C (hu)
CY (1) CY1122773T1 (hu)
DK (1) DK2819516T3 (hu)
ES (1) ES2779032T3 (hu)
HR (1) HRP20200424T1 (hu)
HU (1) HUE048715T2 (hu)
LT (1) LT2819516T (hu)
PL (1) PL2819516T3 (hu)
PT (1) PT2819516T (hu)
SI (1) SI2819516T1 (hu)
WO (1) WO2013019271A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082940A1 (en) 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
KR20160101012A (ko) * 2013-12-09 2016-08-24 뉴로반스, 인크. 신규 조성물
HUE059348T2 (hu) 2015-06-17 2022-11-28 Otsuka America Pharmaceutical Inc Kristályos vegyületek
PT3474844T (pt) 2016-06-28 2022-11-08 Trichomeshell Ltd Uma forma de dosagem para ser vaporizada e fumada
WO2018119291A1 (en) * 2016-12-21 2018-06-28 Otsuka America Pharmaceutical, Inc. Synthetic methods
WO2024048782A1 (en) 2022-09-02 2024-03-07 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20070082940A1 (en) * 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders

Also Published As

Publication number Publication date
CY1122773T1 (el) 2021-05-05
LT2819516T (lt) 2020-05-25
PT2819516T (pt) 2020-03-25
HRP20200424T1 (hr) 2020-09-04
EP2819516A1 (en) 2015-01-07
CA2843847C (en) 2021-05-18
ES2779032T3 (es) 2020-08-13
PL2819516T3 (pl) 2020-08-10
EP2819516B1 (en) 2019-12-25
DK2819516T3 (da) 2020-03-16
WO2013019271A1 (en) 2013-02-07
SI2819516T1 (sl) 2020-07-31
CA2843847A1 (en) 2013-02-07
EP2819516A4 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EP2819516A4 (en) USE OF (1R, 5S) - (+) - 1- (NAPHTALENE-2-YL) -3-AZABICYCLO- {3.1.0-} HEXANE IN THE TREATMENT OF SUFFERED BY MONOAMINE NEUROTRANSMITTERS
IN2014CN02616A (hu)
EP2646019A4 (en) PREPARATION AND USE OF (+) - 1- (3,4-DICHLOROPHENYL) -3-AZABICYCLO- [3.1.0] HEXANE IN THE TREATMENT OF DISEASES AFFECTED BY MONOAMINE-TYPE NEUROTRANSMITTERS
SG10201600618QA (en) Microorganisms and methods for producing 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol and related alcohols
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
AP2014007436A0 (en) A novel 1,2,3,4,-Tetrahydroquinoline derivative useful for the treatment of diabetes
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
ZA201402907B (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
IL232710B (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
HK1192757A1 (zh) 取代的 -芳基- -苯基- -三嗪- -胺
HK1206938A1 (en) Process for the preparation of 3-chloro-4,5,6-trifluoro- picolinonitrile 3--456--
EP2890370A4 (en) AGENTS USEFUL FOR THE TREATMENT OF OBESITY, DIABETES AND RELATED DISORDERS
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
EP2720708A4 (en) AIMING AT THE NEUROMUSCULAR END PLATE FOR TREATMENT PURPOSES
IL232194A0 (en) An improved iontophoretic cross-linking mixture for use in the treatment of keratoconus
LT2882724T (lt) Junginiai, skirti naudoti susirgimų, kurie yra palengvinami slopinant hdac, gydymui
IL228891A (en) 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease
EP2994129A4 (en) Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders
AU2017202012A1 (en) Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo(3.1.0)hexane in the treatment of conditions affected by monoamine neurotransmitters
UY4159Q (es) Motocicleta
ITFI20100058U1 (it) Telaio bicicletta smontabile "wirebike3".
IT1401957B1 (it) Composizione per il trattamento dell'acne.
PL394344A1 (pl) Inhibitor wychwytu zwrotnego serotoniny, jego zastosowanie i sposób syntezy
AU2012265V (en) MJ 511.03 Prunus salicina
AU2012267V (en) MJ 512.01 Prunus salicina